European legislation requires new pharmaceutical packaging to include both the name and strength of the drug in braille on boxes and bottles. Much of the braille on medical packaging is currently produced by an embossing process on boxes. The height of the dots that can be achieved through these methods is less than 0.3 mm. The physical dimensions of the braille cell are not fully standardized throughout different countries in Europe or the world. This lack of standardization can be illustrated by the lack of consistency on the agreed "standard" height of braille dots in different countries, for example, American National Library for the Blind, 0.5 mm; Sweden, 0.25 mm; England (Interline/Interpoint), 0.46 mm; and France, 0.8 to 1.0 mm. In the context of the height of braille required for labeling medicines, there appears to be an inconsistency among production capabilities, braille specifications in different countries, and the lack of evidence of the needs of readers of braille. For this reason, this study aims to investigate the impact of different heights of braille dots on the readability of embossed braille on medicine packaging. (Contains 3 tables and 1 figure.)